Bactrim

Shigellosis, Nocardiosis, Brucellosis + 16 more

Treatment

17 FDA approvals

16 Active Studies for Bactrim

What is Bactrim

Trimethoprim

The Generic name of this drug

Treatment Summary

Sulfamethoxazole is an antibiotic medication used to treat bacterial infections. It works by preventing bacteria from producing folic acid, which is necessary for them to grow and multiply. It is often given in combination with another antibiotic, trimethoprim, to create a stronger effect. This combination is used to treat infections of the urinary, respiratory, and gastrointestinal tracts.

Septra DS

is the brand name

image of different drug pills on a surface

Bactrim Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Septra DS

Trimethoprim

1973

343

Approved as Treatment by the FDA

Trimethoprim, also called Septra DS, is approved by the FDA for 17 uses including Cholera and susceptible Enteritis infectious caused by Shigella sonnei .

Cholera

Used to treat susceptible Cholera in combination with Sulfamethoxazole

susceptible Enteritis infectious caused by Shigella sonnei

Used to treat susceptible Enteritis infectious caused by Shigella sonnei in combination with Sulfamethoxazole

Fluid replacement therapy

Used to treat Fluid replacement therapy in combination with Sulfamethoxazole

Urinary tract infection

Used to treat Urinary Tract Infection caused by susceptible bacteria in combination with Sulfamethoxazole

Nocardiosis

Used to treat Nocardiosis in combination with Sulfamethoxazole

Pneumonia, Pneumocystis

Used to treat Pneumocystis Jirovecii Pneumonia in combination with Sulfamethoxazole

Genus Pneumocystis

Used to treat risk of Pneumocystis jiroveci pneumonia (PCP) in combination with Sulfamethoxazole

Otitis Media

Used to treat Acute Otitis Media caused by susceptible bacteria in combination with Sulfamethoxazole

Brucellosis

Used to treat Brucellosis in combination with Rifampicin

Electrolyte replacement

Used to treat Electrolyte replacement in combination with Sulfamethoxazole

Pneumocystis Jirovecii Pneumonia

Used to treat Pneumocystis Jirovecii Pneumonia in combination with Sulfamethoxazole

Shigellosis

Used to treat Dysentery, Bacillary in combination with Sulfamethoxazole

Bronchitis

Used to treat Acute Exacerbation of Chronic Bronchitis (AECB) caused by susceptible bacteria in combination with Sulfamethoxazole

Diarrhea

Used to treat susceptible Travelers' Diarrhea caused by Enterotoxigenic E. Coli (ETEC) Infection in combination with Sulfamethoxazole

susceptible Enteritis infectious caused by Shigella flexneri

Used to treat susceptible Enteritis infectious caused by Shigella flexneri in combination with Sulfamethoxazole

Brucellosis

Used to treat Brucellosis in combination with Rifampicin

Immunocompromised

Used to treat Immunocompromised in combination with Sulfamethoxazole

Effectiveness

How Bactrim Affects Patients

Sulfamethoxazole is an antibiotic that stops bacteria from making a certain chemical needed to grow. It is usually given with trimethoprim, another antibiotic that works in a different way. Together, sulfamethoxazole and trimethoprim are more effective at stopping the growth of bacteria than either one alone. However, taking sulfamethoxazole can cause allergic reactions, including rashes, Stevens-Johnson syndrome, and toxic epidermal necrolysis. It may also lead to a folate deficiency and cause problems in people with glucose-6-phosphate dehydrogenase deficiency.

How Bactrim works in the body

Sulfamethoxazole stops bacteria from making folic acid, an important molecule for their survival. It does this by mimicking para-aminobenzoic acid, a molecule bacteria use to make folic acid. Sulfamethoxazole tricks the bacteria into using it instead, which stops the bacteria from making folic acid. Without this molecule, bacteria cannot make DNA or other key molecules and die.

When to interrupt dosage

The advised dose of Bactrim is contingent upon the diagnosed condition, including Urinary tract infection, Pneumocystis Jirovecii Pneumonia and Fluid replacement therapy. The measure of dosage fluctuates, in line with the delivery technique delineated in the table below.

Condition

Dosage

Administration

Conjunctivitis, Bacterial

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Solution / drops, Liquid, Liquid - Ophthalmic, Liquid - Intravenous, Injection

Pneumonia, Pneumocystis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Solution / drops, Liquid, Liquid - Ophthalmic, Liquid - Intravenous, Injection

Brucellosis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Solution / drops, Liquid, Liquid - Ophthalmic, Liquid - Intravenous, Injection

Immunocompromised

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Solution / drops, Liquid, Liquid - Ophthalmic, Liquid - Intravenous, Injection

Nocardiosis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Solution / drops, Liquid, Liquid - Ophthalmic, Liquid - Intravenous, Injection

Urinary tract infection

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Solution / drops, Liquid, Liquid - Ophthalmic, Liquid - Intravenous, Injection

bacterial blepharitis caused by susceptible bacteria

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Solution / drops, Liquid, Liquid - Ophthalmic, Liquid - Intravenous, Injection

Urinary tract infection

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Solution / drops, Liquid, Liquid - Ophthalmic, Liquid - Intravenous, Injection

Diarrhea

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Solution / drops, Liquid, Liquid - Ophthalmic, Liquid - Intravenous, Injection

Shigellosis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Solution / drops, Liquid, Liquid - Ophthalmic, Liquid - Intravenous, Injection

Electrolyte replacement

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Solution / drops, Liquid, Liquid - Ophthalmic, Liquid - Intravenous, Injection

Fluid replacement therapy

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Solution / drops, Liquid, Liquid - Ophthalmic, Liquid - Intravenous, Injection

Genus Pneumocystis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Solution / drops, Liquid, Liquid - Ophthalmic, Liquid - Intravenous, Injection

Bacterial conjunctivitis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Solution / drops, Liquid, Liquid - Ophthalmic, Liquid - Intravenous, Injection

Bronchitis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Solution / drops, Liquid, Liquid - Ophthalmic, Liquid - Intravenous, Injection

susceptible Enteritis infectious caused by Shigella flexneri

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Solution / drops, Liquid, Liquid - Ophthalmic, Liquid - Intravenous, Injection

susceptible Enteritis infectious caused by Shigella sonnei

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Solution / drops, Liquid, Liquid - Ophthalmic, Liquid - Intravenous, Injection

Otitis Media

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Solution / drops, Liquid, Liquid - Ophthalmic, Liquid - Intravenous, Injection

Cholera

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Suspension, Suspension - Oral, Solution, Solution - Oral, Solution - Ophthalmic, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Injection - Intravenous, Solution / drops, Liquid, Liquid - Ophthalmic, Liquid - Intravenous, Injection

Warnings

Bactrim has seven contraindications and should not be consumed when experiencing the stipulated conditions in the following table.

Bactrim Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Trimethoprim may interact with Pulse Frequency

Purpura, Thrombocytopenic, Idiopathic

Do Not Combine

hepatic damage

Do Not Combine

Megaloblastic anemia caused by Folate deficiency

Do Not Combine

unable to monitor renal function

Do Not Combine

Disease

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Trimethoprim may interact with Pulse Frequency

There are 20 known major drug interactions with Bactrim.

Common Bactrim Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The excretion of Abemaciclib can be decreased when combined with Trimethoprim.

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Trimethoprim.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Trimethoprim.

Cisplatin

Major

The serum concentration of Cisplatin can be increased when it is combined with Trimethoprim.

Clofarabine

Major

The serum concentration of Clofarabine can be increased when it is combined with Trimethoprim.

Bactrim Toxicity & Overdose Risk

The toxic dose of sulfamethoxazole in mice and rats is 2300 mg/kg and 6200 mg/kg respectively. Signs of an overdose may include loss of appetite, abdominal pain, nausea, vomiting, dizziness, headaches, drowsiness, and loss of consciousness. More serious symptoms like fever, blood in the urine, and crystal formation in the urine have also been reported. Treatment should be focused on relieving the symptoms and may include cleaning out the stomach or inducing vomiting. Monitor lab work to check for any blood or electrolyte issues.

image of a doctor in a lab doing drug, clinical research

Bactrim Novel Uses: Which Conditions Have a Clinical Trial Featuring Bactrim?

Eight ongoing trials are assessing the potential of Bactrim to provide immunocompromised individuals, individuals undergoing fluid replacement therapy, and individuals susceptible to Enteritis infectious caused by Shigella sonnei with therapeutic relief.

Condition

Clinical Trials

Trial Phases

Urinary tract infection

0 Actively Recruiting

Bacterial conjunctivitis

0 Actively Recruiting

Bronchitis

0 Actively Recruiting

Nocardiosis

0 Actively Recruiting

Shigellosis

0 Actively Recruiting

Brucellosis

0 Actively Recruiting

bacterial blepharitis caused by susceptible bacteria

0 Actively Recruiting

Immunocompromised

2 Actively Recruiting

Phase 1, Not Applicable

Otitis Media

0 Actively Recruiting

Genus Pneumocystis

0 Actively Recruiting

Conjunctivitis, Bacterial

0 Actively Recruiting

Fluid replacement therapy

0 Actively Recruiting

Cholera

0 Actively Recruiting

Urinary tract infection

0 Actively Recruiting

susceptible Enteritis infectious caused by Shigella sonnei

0 Actively Recruiting

Pneumonia, Pneumocystis

2 Actively Recruiting

Phase 3, Phase 4

susceptible Enteritis infectious caused by Shigella flexneri

0 Actively Recruiting

Electrolyte replacement

0 Actively Recruiting

Diarrhea

12 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 1

Bactrim Reviews: What are patients saying about Bactrim?

5

Patient Review

2/2/2022

Bactrim for infection

I had really bad acne for over 15 years, but this treatment completely changed my life. I would highly recommend it to anyone who has been struggling with a similar issue.

5

Patient Review

4/18/2022

Bactrim for Skin Infection

I saw a significant improvement in my condition within just a few days, and I didn't experience any negative side effects. This is definitely a great antibiotic!

3

Patient Review

5/23/2019

Bactrim for Bacterial Urinary Tract Infection

Bactrim quickly and effectively cleared up my UTI with minimal side effects.

3

Patient Review

4/6/2019

Bactrim for Skin Infection

2.3

Patient Review

6/12/2022

Bactrim for Bacterial Urinary Tract Infection

Unfortunately, I had to stop taking this medication after only three days due to some serious side effects. These included an irregular heartbeat, hallucinations, and body pains. I had never experienced anything like this before, and it was honestly quite scary. In my opinion, this drug should not be legal.

2.3

Patient Review

6/30/2020

Bactrim for Urinary Tract Infection Prevention

I started seeing floaters and my eyes became red and painful after only five days of taking this medication for prostatitis. I would never recommend it to anyone.

2

Patient Review

2/25/2020

Bactrim for Bacterial Urinary Tract Infection

I had a really bad reaction to this medicine. I developed hives and my eyes swelled up so much I could barely open one of them. If you have any kind of allergy, stay away from this stuff!

1

Patient Review

9/22/2022

Bactrim for Bacterial Urinary Tract Infection

I had an horrendous reaction to this medication, 10 minutes after taking the first pill. I began itching uncontrollably and welts started forming where I was scratching myself. My face, neck, and arms were covered in hives. Thankfully, my doctor was able to send me another prescription for a different antibiotic pretty quickly.

1

Patient Review

12/8/2019

Bactrim for Urinary Tract Infection Prevention

I was prescribed Bactum for a UTI, but it turns out I didn't even have one. I took the pill as directed, and by 10AM my whole body was itching terribly. My eyes turned bloodshot red and my vision became so blurred that I could hardly see. It was terrifying. I had to go to urgent care and get a steroid shot, and now I have to take another pill.

1

Patient Review

5/16/2020

Bactrim for Bacterial Urinary Tract Infection

After just one dose of this medication, I experienced a high fever, chills, and nausea. I took the second dose anyway, and then promptly threw up multiple times. Even now, two days later, I'm still feeling the effects of this drug in terms of fatigue and headaches.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about bactrim

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Bactrim strong antibiotic?

"Bactrim is a strong antibiotic. It is a potent drug combination used to treat opportunistic infections of pneumonia, skin, bronchitis, traveler's diarrhea, respiratory and intestine infections."

Answered by AI

What is Bactrim treat used for?

"This medication is a combination of two antibiotics known as sulfamethoxazole and trimethoprim. It can be used to treat a number of different bacterial infections, such as those affecting the middle ear, respiratory system or intestines. It can also be used to prevent a certain type of pneumonia known as pneumocystis pneumonia."

Answered by AI

Is Bactrim a good antibiotic for UTI?

"A three-day course of trimethoprim-sulfamethoxazole (TMP/SMX) is recommended for treating uncomplicated urinary tract infections (UTIs), in areas where the rate of resistance for Escherichia coli bacteria is less than 20 percent."

Answered by AI

What infections are Bactrim good for?

"Bactrim consists of two antibiotics, sulfamethoxazole and trimethoprim, which are used to treat various bacterial infections, including those of the urinary tract, ear, bronchus, and intestine. It can also be used to treat traveler's diarrhea and methicillin-resistant staphylococcus aureus (MRSA)."

Answered by AI

Clinical Trials for Bactrim

Image of McGill university Health Centre (Royal victoria Hospital and Montreal General Hospital in Montreal, Canada.

Systemic Corticosteroids for Pneumocystis Pneumonia

18+
All Sexes
Montreal, Canada

The HOW LONG trial is an international, multicenter, Phase IV randomized clinical trial evaluating the optimal duration of adjunctive systemic corticosteroids in immunocompromised adults with severe Pneumocystis jirovecii pneumonia (PCP) who demonstrate early clinical recovery. Participants who no longer require supplemental oxygen by day 10 of corticosteroid therapy are randomized to discontinue corticosteroids at day 10 (or hospital discharge, if earlier) versus continue corticosteroids for a total of 21 days. The trial assesses whether earlier discontinuation reduces steroid-related complications while maintaining clinical outcomes.

Phase 4
Waitlist Available

McGill university Health Centre (Royal victoria Hospital and Montreal General Hospital

Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA

While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.

Phase < 1
Waitlist Available

Stanford Digestive Health Clinic (+1 Sites)

Sean P Spencer, MD, PhD

Have you considered Bactrim clinical trials?

We made a collection of clinical trials featuring Bactrim, we think they might fit your search criteria.
Go to Trials
Image of University of Maryland, School of Medicine, Center for Vaccine Development and Global Health in Baltimore, United States.

Vaccine for E. coli Infections

18 - 49
All Sexes
Baltimore, MD

The study is designed to evaluate the safety, immunogenicity, and efficacy of the intramuscular administration of a CS6 based vaccine (CssBA) against ETEC co-administered with double mutant labile toxin (dmLT) in preventing moderate-severe diarrhea (MSD) following challenge with ETEC strain B7A in healthy adults. Approximately 72 adult participants, divided into 4 cohorts of 18, will be randomized 1:1 to receive vaccine (45 micrograms CssBA with 0.5 micrograms dmLT) or placebo (normal saline) on an outpatient basis. All participants will receive 3 intramuscular (IM) doses of vaccine or placebo at 3-week intervals (days 1, 22 and 43). Following vaccination, participants will be followed as outpatients for safety using a memory aid from the time of each vaccination through 7 days post each vaccination. Approximately 28 days (plus or minus 1 day) after receipt of the 3rd dose of study agent, participants meeting challenge criteria will be admitted to an inpatient unit and be administered an oral dose of 1 x 10\^10 cfu (colony-forming unit) of ETEC strain B7A. Five days after challenge, participants will be treated with ciprofloxacin, except in cases of known allergy or intolerance. Participants will be discharged from the inpatient unit when they have completed their 3-day antibiotic course and are able to care for themselves. After discharge from the inpatient unit, participants will return for clinic visits and have a phone visit to provide any updates on medication, medical history and AE/SAEs. The primary objectives are: 1) Estimate CssBA+dmLT efficacy in preventing moderate-severe diarrhea (MSD) following challenge with ETEC strain B7A in healthy adults. 2) Evaluate the safety of intramuscular injection of CssBA+dmLT.

Phase 2
Waitlist Available

University of Maryland, School of Medicine, Center for Vaccine Development and Global Health (+1 Sites)

Have you considered Bactrim clinical trials?

We made a collection of clinical trials featuring Bactrim, we think they might fit your search criteria.
Go to Trials
Image of McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital) in Montreal, Canada.

Low-Dose Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia

18 - 100
All Sexes
Montreal, Canada

Pneumocystis jirovecii pneumonia (PJP) is an opportunistic fungal infection of immunocompromised hosts which causes in significant morbidity and mortality. The current standard of care, trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 15-20 mg/kg/day of TMP, is associated with serious adverse events, including hypersensitivity reactions, drug-induced liver injury, cytopenia, and renal failure occurring among 20-60% of patients. The frequency of adverse events increases in a dose dependent manner and commonly limits the use of TMP-SMX. Reduced treatment doses of TMP-SMX for PJP reduced ADEs without mortality differences in a recent meta-analysis of observational studies. We therefore propose a Phase III randomized, placebo-controlled trial to directly compare the efficacy and safety of low dose (10 mg/kg/day of TMP) compared to the standard-of-care (15 mg/kg/day) among patients with PJP for the primary outcome of death, new mechanical ventilation, and change of treatment.

Phase 3
Waitlist Available

McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)

Emily G McDonald, MD MSc

Have you considered Bactrim clinical trials?

We made a collection of clinical trials featuring Bactrim, we think they might fit your search criteria.
Go to Trials